{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:37:30Z","timestamp":1793972250932,"version":"4.8.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There is no recognized serum biomarker to predict the recurrence of endometrial carcinoma (EC). We aimed to explore serum human epididymis protein 4 (HE4) and cancer antigen 125 (CA125) as the biomarkers to predict and monitor recurrence of type II EC. 191 patients diagnosed with type II EC were involved for this retrospective study. Comparing recurrent with non-recurrent patients, HE4 levels resulted a statistically significant difference at primary diagnosis and recurrence, respectively (P\u2009=\u20090.002 and P\u2009=\u2009&lt;\u20090.001), while CA125 levels resulted statistically significant (P\u2009=\u2009&lt;\u20090.001) at recurrence. According to receiver operating characteristic curve analysis, the areas under the curve were significant for HE4 levels at primary diagnosis and recurrence predicting recurrence. Furthermore, CA125 levels at recurrence were significant. And the combination of both markers showed the higher sensitivity and specificity than single one. Patients with higher HE4 levels were associated with worse disease-free survival and overall survival, the opposite was true for patients with lower HE4 levels. The preoperative HE4 levels could be used to evaluate the risk factors of type II EC. Which suggested that HE4 levels might associated with the prognosis of type II EC. And combination of HE4 and CA125 could be applied to monitor recurrence during follow-up.<\/jats:p>","DOI":"10.1038\/s41598-021-01263-w","type":"journal-article","created":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T11:37:43Z","timestamp":1636025863000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Serum HE4 and CA125 combined to predict and monitor recurrence of type II endometrial carcinoma"],"prefix":"10.1038","volume":"11","author":[{"given":"Quan","family":"Quan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanchun","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuwei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sainan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,4]]},"reference":[{"key":"1263_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin. 68, 7\u201330. https:\/\/doi.org\/10.3322\/caac.21442 (2018).","journal-title":"CA Cancer J. Clin."},{"issue":"Suppl 1","key":"1263_CR2","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1016\/S0020-7292(06)60031-3","volume":"95","author":"WT Creasman","year":"2006","unstructured":"Creasman, W. T. et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int. J. Gynaecol. Obstet. 95(Suppl 1), S105-143. https:\/\/doi.org\/10.1016\/S0020-7292(06)60031-3 (2006).","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"1263_CR3","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ygyno.2006.02.011","volume":"101","author":"M Fung-Kee-Fung","year":"2006","unstructured":"Fung-Kee-Fung, M. et al. Follow-up after primary therapy for endometrial cancer: A systematic review. Gynecol. Oncol. 101, 520\u2013529. https:\/\/doi.org\/10.1016\/j.ygyno.2006.02.011 (2006).","journal-title":"Gynecol. Oncol."},{"key":"1263_CR4","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.bpobgyn.2014.04.008","volume":"28","author":"AC Testa","year":"2014","unstructured":"Testa, A. C. et al. Which imaging technique should we use in the follow up of gynaecological cancer?. Best Pract. Res. Clin. Obstet. 28, 769\u2013791. https:\/\/doi.org\/10.1016\/j.bpobgyn.2014.04.008 (2014).","journal-title":"Best Pract. Res. Clin. Obstet."},{"key":"1263_CR5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ygyno.2016.12.010","volume":"144","author":"AA Suarez","year":"2017","unstructured":"Suarez, A. A., Felix, A. S. & Cohn, D. E. Bokhman redux: Endometrial cancer \u201ctypes\u201d in the 21st century. Gynecol. Oncol. 144, 243\u2013249. https:\/\/doi.org\/10.1016\/j.ygyno.2016.12.010 (2017).","journal-title":"Gynecol. Oncol."},{"key":"1263_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/ijgo.12608","volume":"143","author":"N Bhatla","year":"2018","unstructured":"Bhatla, N. & Denny, L. FIGO cancer report 2018. Int. J. Gynecol. Obstet. 143, 2\u20133. https:\/\/doi.org\/10.1002\/ijgo.12608 (2018).","journal-title":"Int. J. Gynecol. Obstet."},{"key":"1263_CR7","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ygyno.2009.06.011","volume":"115","author":"DM Boruta","year":"2009","unstructured":"Boruta, D. M., Gehrig, P. A., Fader, A. N. & Olawaiye, A. B. Management of women with uterine papillary serous cancer: A Society of Gynecologic Oncology (SGO) review. Gynecol. Oncol. 115, 142\u2013153. https:\/\/doi.org\/10.1016\/j.ygyno.2009.06.011 (2009).","journal-title":"Gynecol. Oncol."},{"key":"1263_CR8","first-page":"29","volume":"22","author":"V Paunovic","year":"2017","unstructured":"Paunovic, V., Protrka, Z., Ardalic, D. & Paunovic, T. Usefulness of human epididymis protein 4 in predicting optimal cytoreductive therapy in patients with advanced ovarian cancer. J. Buon 22, 29\u201333 (2017).","journal-title":"J. Buon"},{"key":"1263_CR9","first-page":"1010","volume":"27","author":"K Abbink","year":"2017","unstructured":"Abbink, K. et al. He4 is superior to Ca125 in the detection of recurrent disease in the follow-up of high risk endometrial cancer patients. Int. J. Gynecol. Cancer 27, 1010\u20131010 (2017).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"1263_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1028-0","author":"DJ Brennan","year":"2015","unstructured":"Brennan, D. J. et al. Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance. BMC Cancer https:\/\/doi.org\/10.1186\/s12885-015-1028-0 (2015).","journal-title":"BMC Cancer"},{"key":"1263_CR11","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/sj.bjc.6605011","volume":"100","author":"K Huhtinen","year":"2009","unstructured":"Huhtinen, K. et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br. J. Cancer 100, 1315\u20131319. https:\/\/doi.org\/10.1038\/sj.bjc.6605011 (2009).","journal-title":"Br. J. Cancer"},{"key":"1263_CR12","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1158\/0008-5472.Can-04-3924","volume":"65","author":"R Drapkin","year":"2005","unstructured":"Drapkin, R. et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometriold ovarian carcinomas. Cancer Res. 65, 2162\u20132169. https:\/\/doi.org\/10.1158\/0008-5472.Can-04-3924 (2005).","journal-title":"Cancer Res."},{"key":"1263_CR13","doi-asserted-by":"publisher","first-page":"170","DOI":"10.6004\/jnccn.2018.0006","volume":"16","author":"WJ Koh","year":"2018","unstructured":"Koh, W. J. et al. Uterine neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 16, 170\u2013199 (2018).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"1263_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ijgo.2009.02.012","volume":"105","author":"S Pecorelli","year":"2009","unstructured":"Pecorelli, S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int. J. Gynaecol. Obstet. 105, 103\u2013104. https:\/\/doi.org\/10.1016\/j.ijgo.2009.02.012 (2009).","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"1263_CR15","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1007\/s13277-015-4324-z","volume":"37","author":"R Angioli","year":"2016","unstructured":"Angioli, R. et al. The role of HE4 in endometrial cancer recurrence: How to choose the optimal follow-up program. Tumor Biol. 37, 4973\u20134978. https:\/\/doi.org\/10.1007\/s13277-015-4324-z (2016).","journal-title":"Tumor Biol."},{"key":"1263_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3109\/01443615.2016.1174199","volume":"37","author":"SA Yilmaz","year":"2017","unstructured":"Yilmaz, S. A. et al. The role of human epididymis secretory protein E4 in patients with endometrial cancer and premalignant endometrial lesions. J. Obstet. Gynaecol. 37, 58\u201363. https:\/\/doi.org\/10.3109\/01443615.2016.1174199 (2017).","journal-title":"J. Obstet. Gynaecol."},{"key":"1263_CR17","doi-asserted-by":"publisher","first-page":"XC01","DOI":"10.7860\/JCDR\/2017\/28926.10285","volume":"11","author":"R Dewan","year":"2017","unstructured":"Dewan, R., Dewan, A., Hare, S., Bhardwaj, M. & Mehrotra, K. Diagnostic performance of serum human epididymis protein 4 in endometrial carcinoma: A Pilot Study. J. Clin. Diagn. Res. 11, XC01\u2013XC05. https:\/\/doi.org\/10.7860\/JCDR\/2017\/28926.10285 (2017).","journal-title":"J. Clin. Diagn. Res."},{"key":"1263_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/ijgo.12010","volume":"136","author":"Y Wang","year":"2017","unstructured":"Wang, Y. et al. Predictive value of serum HE4 and CA125 concentrations for lymphatic metastasis of endometrial cancer. Int. J. Gynaecol. Obstet. 136, 58\u201363. https:\/\/doi.org\/10.1002\/ijgo.12010 (2017).","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"1263_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ygyno.2013.10.036","volume":"132","author":"DJ Brennan","year":"2014","unstructured":"Brennan, D. J. et al. Serum HE4 as a prognostic marker in endometrial cancer\u2014A population based study. Gynecol. Oncol. 132, 159\u2013165. https:\/\/doi.org\/10.1016\/j.ygyno.2013.10.036 (2014).","journal-title":"Gynecol. Oncol."},{"key":"1263_CR20","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1111\/aogs.12235","volume":"92","author":"SL Antonsen","year":"2013","unstructured":"Antonsen, S. L. et al. HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: A prospective multicenter study (ENDOMET). Acta Obstet. Gynecol. Scand. 92, 1313\u20131322. https:\/\/doi.org\/10.1111\/aogs.12235 (2013).","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"1263_CR21","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ygyno.2012.04.022","volume":"126","author":"I Mutz-Dehbalaie","year":"2012","unstructured":"Mutz-Dehbalaie, I. et al. HE4 is an independent prognostic marker in endometrial cancer patients. Gynecol. Oncol. 126, 186\u2013191. https:\/\/doi.org\/10.1016\/j.ygyno.2012.04.022 (2012).","journal-title":"Gynecol. Oncol."},{"key":"1263_CR22","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/1096-9098(200012)75:4<264::Aid-Jso7>3.0.Co;2-Q","volume":"75","author":"P Buamah","year":"2000","unstructured":"Buamah, P. Benign conditions associated with raised serum CA-125 concentration. J. Surg. Oncol. 75, 264\u2013265. https:\/\/doi.org\/10.1002\/1096-9098(200012)75:4%3c264::Aid-Jso7%3e3.0.Co;2-Q (2000).","journal-title":"J. Surg. Oncol."},{"key":"1263_CR23","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1080\/14737159.2016.1251317","volume":"16","author":"WL Qu","year":"2016","unstructured":"Qu, W. L. et al. Physiopathological factors affecting the diagnostic value of serum HE4-test for gynecologic malignancies. Expert Rev. Mol. Diagn. 16, 1271\u20131282. https:\/\/doi.org\/10.1080\/14737159.2016.1251317 (2016).","journal-title":"Expert Rev. Mol. Diagn."},{"key":"1263_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8111784","author":"V Dochez","year":"2019","unstructured":"Dochez, V. et al. Efficacy of HE4, CA125, risk of malignancy index and risk of ovarian malignancy index to detect ovarian cancer in women with presumed benign ovarian tumours: A prospective, multicentre trial. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm8111784 (2019).","journal-title":"J. Clin. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01263-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01263-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01263-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T17:03:24Z","timestamp":1670087004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01263-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,4]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1263"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-01263-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,4]]},"assertion":[{"value":"24 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21694"}}